The Talent Problem in Radioligand Therapy that Nobody is Talking About

But as more organisations move toward building manufacturing capability, a different constraint is becoming visible, not in the science, but in the operational model required to deliver it.

Radioligand manufacturing does not behave like conventional biologics. The isotope does not wait. When a batch is ready, it either moves or it decays. That physics-driven reality changes the entire operational model and the talent required to run it.

Conventional biologics manufacturing involves tight tolerances and regulated processes, but most of its constraints are biological and chemical in nature. Radioligand manufacturing adds a third dimension: physics. The radioactive decay of the therapeutic isotope means that every step in manufacturing, QC, and release operates under a time pressure that cannot be extended, negotiated, or worked around.

Lutetium-177, currently the most widely used therapeutic isotope in clinical development, has a half-life of approximately 6.6 days. That window governs everything. Product produced on a given date must be qualified, released, shipped, and administered within a timeline that leaves no room for QC delays, documentation errors, or release queue backlogs. A sterility test requiring 14 days of incubation, standard for many biologics, is simply not compatible with Lu-177 release logistics. Rapid, alternative, and risk-based release strategies are not optional. They are structural requirements.

Alpha emitters such as Actinium-225 further compress this. With a half-life of approximately 10 days and QC requirements the IAEA describes as intricate, Ac-225 programmes sit at the leading edge of operational complexity in this space, with infrastructure, training, and procedural demands of a different order from standard radiopharmaceutical production.

In practice, this creates a set of operational requirements with no parallel in standard biologics:

• QC must be structured around isotope decay timelines, not conventional incubation periods
• Rapid release strategies, alternative sterility methods, and real-time QC monitoring are operational necessities, not enhancements
• Radiation safety, hot-cell operations, and radioactive waste management impose facility and personnel requirements unique to this modality
• Supply chain planning must account for reactor production schedules, transport logistics, and isotope availability simultaneously

In this environment, there is no buffer.

The rapid growth of RLT clinical programmes is creating demand for therapeutic isotopes that the current supply infrastructure was not designed to meet. Mo-99, the parent isotope for diagnostic imaging and a reference point for supply chain vulnerability, is produced by a limited number of nuclear reactors globally. The OECD Nuclear Energy Agency has documented how extended planned maintenance periods and unplanned outages at operating reactors can overlap, creating downstream supply disruptions that directly affect patients.

Lu-177 faces the same risk at commercial scale. Demand growth driven by the expansion of PSMA-targeted and SSTR-targeted programmes is outpacing the production capacity of existing reactors, and a 2021 analysis identified Lu-177 as at potential risk of future shortage. The OECD NEA has also noted that as the number of supply chain participants decreases, the ability to cover weaknesses during stress events diminishes. This is a structural concern for a modality that is adding commercial programmes at the current rate.

A manufacturing site capable of producing a radioligand product remains dependent on a supply chain built for a much smaller market. As commercial volumes grow, isotope availability becomes a programme risk, not just a procurement conversation.

What brings these constraints together is the workforce required to operate within them.

Radioligand manufacturing requires professionals who possess a combination of competencies that are not widely available: pharmaceutical GMP expertise, radiochemistry or nuclear medicine operations experience, radiation safety qualifications, and familiarity with the regulatory frameworks governing both pharmaceutical products and radioactive materials. These are not adjacent skill sets that can be bridged with modest retraining. They represent genuinely separate professional disciplines that happen to converge in RLT manufacturing.

The result is a talent market where the roles most critical to RLT programme delivery are the hardest to fill and the slowest to develop:

Radiochemists and radiopharmacists with GMP manufacturing experience
QC scientists with expertise in rapid release and alternative sterility methods for short shelf-life radiopharmaceuticals
QA specialists and QPs with radiopharmaceutical batch certification experience
Radiation safety officers qualified to manage hot-cell operations and radioactive waste
Production and operations leaders experienced in decay-timed logistics and isotope supply coordination

These profiles are genuinely rare, and demand for them is growing faster than supply.

Novartis’ investment in a dedicated 46,000-square-foot RLT manufacturing facility in Denton, Texas, expected to be operational in 2028, signals where the largest organisations see this market heading. Mid-scale organisations and CDMOs competing in the same space face the same talent requirements but lack the same brand visibility or long-term programme pipeline to attract candidates.

In most manufacturing environments, capacity gaps create delays. In radioligand therapy, they create missed windows.

Because the product is time-sensitive, a delay in any part of the release chain, QC, documentation, QP review, or logistics coordination directly affects whether the product reaches the patient at all. A batch that misses its administration window due to a release delay is not a commercial inconvenience. For the patient waiting for it, it is a clinical setback.

This is why organisations entering RLT manufacturing for the first time consistently underestimate staffing requirements at launch. A QA team sized for a standard biologics product is not sized for a radiopharmaceutical with a six-day release window. These structural mismatches become visible quickly once production begins.

The organisations managing RLT manufacturing well are not those that hired fastest when the pressure arrived. They are the ones that engaged the right talent early, before operational launch, before the first batch was in the hot cell, before the QC timeline was under isotope pressure.

Radiation safety qualifications take time. Radiopharmaceutical QA experience is built through exposure that cannot be compressed. Production leaders who understand isotope logistics are not retrained in weeks. These organisations recognise that, and they invest in building capability rather than relying on immediate availability.

This approach mirrors what we see more broadly across advanced therapies. Hiring is treated as a programme dependency, planned and resourced with the same rigour as facility qualification or regulatory strategy, not as a downstream activity.

Radioligand therapy will continue to expand, and the clinical pipeline supports that trajectory. But operational success will depend on the ability to build and retain highly specialised manufacturing teams within a constrained talent market.

For many organisations, the limiting factor is no longer whether they can develop the therapy; it is whether they can deliver it. It is whether they can consistently produce and deliver it, within a window that cannot move.

And that is ultimately a question of talent.